---
title: "Candel Therapeutics 将在 SITC 2025 年年会上发表演讲"
description: "马萨诸塞州尼德汉，2025 年 10 月 3 日（GLOBE NEWSWIRE）-- Candel Therapeutics, Inc.（Candel 或公司）（NASDAQ:CADL），一家专注于开发多模式生物免疫疗法以帮助患者抗击癌症的临床阶段生物制药公司，今天宣布公司将展示"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/259903393.md"
published_at: "2025-10-03T14:07:55.000Z"
---

# Candel Therapeutics 将在 SITC 2025 年年会上发表演讲

> 马萨诸塞州尼德汉，2025 年 10 月 3 日（GLOBE NEWSWIRE）-- Candel Therapeutics, Inc.（Candel 或公司）（NASDAQ:CADL），一家专注于开发多模式生物免疫疗法以帮助患者抗击癌症的临床阶段生物制药公司，今天宣布公司将展示

NEEDHAM, Mass., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Candel Therapeutics, Inc. ( Candel or the Company ) ( NASDAQ:CADL ) , a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present ...

### Related Stocks

- [CADL.US - Candel Therapeutics](https://longbridge.com/zh-CN/quote/CADL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | NEEDHAM, Mass., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Candel Therapeutics, Inc. ( Candel or the Company ) ( Nasdaq: CADL ) | [Link](https://longbridge.com/zh-CN/news/265748723.md) |
| Hansa Biopharma reports Q4 results | Hansa Biopharma reports Q4 results | [Link](https://longbridge.com/zh-CN/news/275587443.md) |
| 14:02 ETFlorida Cancer Specialists & Research Institute Celebrates Opening of New St. Petersburg Bayfront Location at Orlando Health Institute Square | Florida Cancer Specialists & Research Institute (FCS) has opened a new 31,000 square-foot facility at Orlando Health Ins | [Link](https://longbridge.com/zh-CN/news/275937392.md) |
| Aktis Oncology's Quiet Period Set To End  on February 18th (NASDAQ:AKTS) | Aktis Oncology's quiet period will end on February 18th, following its IPO on January 9th, where it issued 17,650,000 sh | [Link](https://longbridge.com/zh-CN/news/275561332.md) |
| NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection \| NEO Stock News | NeoGenomics, Inc. has launched PanTracer Pro, a new integrated testing approach aimed at improving the selection of ther | [Link](https://longbridge.com/zh-CN/news/275753736.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
